Open AccessCardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
Author(s) -
William B. White,
Kenneth G. Saag,
Michael A. Becker,
Jeffrey Borer,
Philip B. Gorelick,
Andrew Whelton,
Barbara Hunt,
Majin Castillo,
Lhanoo Gunawardhana
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1710895
Subject(s) - febuxostat , allopurinol , gout , medicine , hyperuricemia , uric acid
Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom